Literature DB >> 9918878

Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele.

C Oberst1, M Hartl, R Weiskirchen, K Bister.   

Abstract

To investigate the molecular basis of oncogenesis induced by the v-myc oncogene of avian myelocytomatosis virus MC29, we developed a conditional cell transformation system in which expression of the MC29 v-myc allele is dependent on a doxycycline-sensitive transactivator (tTA). Clonal lines of quail embryo fibroblasts transformed by doxycycline-controlled v-myc revert to the normal phenotype and lose their ability to grow in soft agar after the addition of doxycycline. Repression of v-myc causes the cells to withdraw from the cell cycle, and long-term survival in culture requires reexpression of v-myc. Although complete repression of v-myc mRNA and v-Myc protein in these cells occurs within 14 h after the addition of doxycycline, the first morphological alterations are observed after 24 h, and after 3 days, the morphology changed entirely from small rounded cells showing a typical myc-transformed phenotype to large flat cells resembling normal fibroblasts. Cells exposed to doxycycline for 3 days reexpressed v-myc within 24 h after withdrawal of the drug from the culture medium, partial retransformation occurred after 2 days, and complete morphological transformation was reestablished after 6 days. Analogous results were obtained with a cell line in which expression of the v-myc allele is dependent on a reverse transactivator (rtTA) that is activated by doxycycline. The striking differential expression of known transformation-sensitive genes and of new candidate v-myc target genes revealed the tightness of the doxycycline-controlled v-myc expression system. The data also indicate that expression of v-myc in these cells is indispensable for enhanced proliferation, transformation, and immortalization. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918878     DOI: 10.1006/viro.1998.9499

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Self-renewal induced efficiently, safely, and effective therapeutically with one regulatable gene in a human somatic progenitor cell.

Authors:  Kwang S Kim; Hong J Lee; Han S Jeong; Jianxue Li; Yang D Teng; Richard L Sidman; Evan Y Snyder; Seung U Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-04       Impact factor: 11.205

2.  LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1.

Authors:  R Weiskirchen; M Moser; S Weiskirchen; M Erdel; S Dahmen; R Buettner; A M Gressner
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

3.  Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1).

Authors:  Markus Hartl; Andrea Nist; M Imran Khan; Taras Valovka; Klaus Bister
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

4.  Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein.

Authors:  Jin Shi; Peter K Vogt
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

5.  Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation.

Authors:  Jin Shi; Minghao Sun; Peter K Vogt
Journal:  Oncotarget       Date:  2010-05

6.  Genetic Polymorphisms of the Bovine NOV Gene Are Significantly Associated with Carcass Traits in Korean Cattle.

Authors:  B S Kim; S C Kim; C M Park; S H Lee; S H Cho; N K Kim; G W Jang; D H Yoon; B S Yang; S K Hong; H H Seong; B H Choi
Journal:  Asian-Australas J Anim Sci       Date:  2013-06       Impact factor: 2.509

7.  In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential.

Authors:  Philipp Raffeiner; Ruth Röck; Andrea Schraffl; Markus Hartl; Jonathan R Hart; Kim D Janda; Peter K Vogt; Eduard Stefan; Klaus Bister
Journal:  Oncotarget       Date:  2014-10-15

8.  Tetracycline regulated systems in functional oncogenomics.

Authors:  Arkadiusz Welman; Jane Barraclough; Caroline Dive
Journal:  Transl Oncogenomics       Date:  2007-03-28

9.  Transcriptional control of DNA replication licensing by Myc.

Authors:  Taras Valovka; Manuela Schönfeld; Philipp Raffeiner; Kathrin Breuker; Theresia Dunzendorfer-Matt; Markus Hartl; Klaus Bister
Journal:  Sci Rep       Date:  2013-12-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.